SynthesisRenal failure2021
The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review.
Synthesis in Renal failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- A nomogram to predict hyperkalemia in patients with hemodialysis: a retrospective cohort study.BMC nephrology · 2022Trial
- Efficacy and safety of sodium zirconium cyclosilicate on non-dialysis days for long-term management of chronic hyperkalemia in maintenance hemodialysis: a single-center, prospective, open-label, randomized controlled trial.International urology and nephrology · 2026Article
- Real-world effectiveness of patiromer among hemodialysis patients: a one-year retrospective cohort study.BMC nephrology · 2026Article
- Impact of RAAS blockers on serum potassium and mortality in a large dialysis cohort: a longitudinal analysis.Clinical kidney journal · 2026Article
- A Pilot Randomised Controlled Trial of a Targeted Dietary Approach to Potassium Management in Hemodialysis: A Clinical Research Protocol for the Evidence for Optimal Potassium Intake in Hemodialysis (EvoKe-HD) Study.Canadian journal of kidney health and disease · 2026Article
- Perioperative Management of the Patient Receiving Maintenance Hemodialysis.Anesthesiology · 2025Article
- Prevalence, practice pattern, and mortality of hyperkalemia in Chinese patients undergoing hemodialysis in the visualize HD study.Scientific reports · 2025Observational
- Development and Validation of a Risk Prediction Model for Interdialytic Hyperkalemia in Patients Undergoing Maintenance Hemodialysis.Risk management and healthcare policy · 2025Article
- Hyperkalaemia among hospital admissions: prevalence, risk factors, treatment and impact on length of stay.BMC nephrology · 2024Article
- Associations between serum potassium variability and mortality in patients undergoing maintenance hemodialysis: a retrospective study.Scientific reports · 2024Article
- Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K).Renal failure · 2024Article
- High facility-level serum potassium variability associated with mortality in hemodialysis patients: results from Chinese Dialysis Outcomes and Practice Patterns Study (DOPPS).Renal failure · 2023Article
- Hyperkalaemia prevalence and dialysis patterns in Chinese patients on haemodialysis: an interim analysis of a prospective cohort study (PRECEDE-K).BMC nephrology · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with chronic kidney disease, especially those receiving hemodialysis (HD), are at risk of hyperkalemia (HK). This systematic review aimed to evaluate the prevalence of HK in patients with renal disease receiving HD and collate evidence on the effect of HK and differing HD patterns (i.e., long vs. short inter-dialytic intervals [LIDI and SIDI, respectively] in a thrice weekly schedule) on mortality.
methodsComprehensive searches were conducted across six databases and selected conference proceedings by two independent reviewers up to September 2020. A hundred and two studies reporting frequency of HK, mortality, or cardiovascular (CV) outcomes in adult patients with acute, chronic or end-stage renal disease in receipt of HD were included. Narrative synthesis of results was undertaken with key findings presented in tables and figures.
resultsMedian prevalence of HK in patients with renal disease receiving HD was 21.6% and increased in patients receiving concomitant medications - mainly renin-angiotensin-aldosterone system inhibitors and potassium-sparing diuretics. Associations between elevated potassium levels and increased risk of both all-cause and CV mortality in the HD population were consistent across the included studies. In addition, there was a rise in all-cause and CV mortality on the day following LIDI compared with the day after the two SIDIs in patients on HD.
conclusionsEvidence identified in this systematic review indicates a relationship between HK and LIDI with mortality in patients with renal disease receiving HD, emphasizing the need for effective monitoring and management to control potassium levels both in emergency and chronic HD settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.